DABUR Q1 FY27 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹3,764 Cr
verified against source
Revenue YoY
10.6%
reported change
EBITDA
Pending
latest reported figure
Source
screener in enriched
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Dabur delivered a strong Q1 FY27 with consolidated revenue growth of 10.6%, driven by broad-based performance across India and international markets. India FMCG grew 9.5% with 5% volume growth, while international business accelerated 15.5% in INR terms. The HPC portfolio (12.3% growth) and hair care (double-digit) led domestic performance, with hair oil gaining 102 bps market share and oral care maintaining near double-digit growth. Operating profit grew 11% and PAT increased 15%, outpacing revenue, reflecting successful premiumization and cost management. Management maintained full-year double-digit revenue growth guidance and expects margins to exceed prior year if Middle East geopolitical situation stabilizes. Rural demand continues outperforming urban by 550 bps. Key risks include raw material inflation, monsoon uncertainty (14-15% deficit), and structural competition in glucose from energy drinks. The Rs 500 crore D2C venture fund is actively evaluating acquisition targets with a 3-year timeline for 1-2 sizable deals.
Colored figures show movement against the previous available record.
Guidance to track
- Management maintained guidance for double-digit revenue growth for FY27, expecting revenue to be driven by both volume and price given pass-through of input inflation to consumers.
- Operating margins are expected to exceed prior year levels, contingent on stabilization of Middle East geopolitical situation and crude oil prices.
- Management has allocated Rs 500 crore for D2C venture investments, targeting 1-2 sizable acquisitions over 3 years. Currently in discussions with 2-3 companies; execution depends on negotiation outcomes.
Risks flagged
- War-related disruptions in the Middle East continue to impact input cost trends and supply chain efficiency. Crude-linked inflation requires ongoing price increases that could pressure volume growth if not managed carefully.
- Despite recent recovery (14-15% deficit from initial levels), uneven monsoon across districts could impact farm income and rural consumption. Management flagged this as a watch item for H2 FY27.
- Analyst raised concern about whether glucose faces permanent demand shift given increasing competition from energy drinks. Management cited strong May-June recovery (mid-teens growth) and rural consumption patterns as rebuttal, but category remains structurally vulnerable to portfolio evolution.
- While Bacha expanded to MP, Rajasthan, and Delhi NCR via e-commerce/quick commerce (6% of turnover, triple-digit growth), management acknowledged 'taste disparity' in new markets and slower-than-expected physical distribution build. Scale-up in new states remains a work in progress.
Key quotes
- If the war ends tomorrow then I think the petroleum prices will come down and therefore link inflation will come down and we'll be very confident on delivering a double digit profitable growth in line with top line. If the war continues then it's a wait.
- Volume will not be double digit in any case. I was talking about the top line being double digit will be more driven by revenue and price because of the inflation we had to pass it on to the consumer.
- The science brand is month on month doing well and we are seeing it as a D2C disruptive healthcare play for us. The brand will see an exit of roughly around 50 odd crores of ARR at the end of the year.
Research modules